RxDoctor Payments Data

Osaretin Okungbowa, MD

Family Medicine · Statesboro, GANPI 1740474154

Payments from drug & device makers

$1,569in general payments, 2019–2025

Across 79 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$315
  • GSK$230
  • AbbVie$224
  • Amgen$161
  • Novo Nordisk$122
  • Bayer$108
  • plus $408 from 11 others

What the payments were for

  • Food & beverage$1,49795%
  • Education$725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,569 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$94,011
Medicare patients
109
Services billed
1,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide213$243,558
JardianceEmpagliflozin173$114,707
EliquisApixaban133$101,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$86,133
FarxigaDapagliflozin Propanediol104$72,966
EntrestoSacubitril/Valsartan66$67,300
LinzessLinaclotide78$66,530
RybelsusSemaglutide68$63,954
KerendiaFinerenone83$61,461
TradjentaLinagliptin94$55,856
JanuviaSitagliptin Phosphate60$53,082
MounjaroTirzepatide34$35,665
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$33,560
XareltoRivaroxaban36$27,861
Tresiba Flextouch U-200Insulin Degludec34$25,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Tresiba$122$316,408292 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$315$117,795174 claims
AbbVieLinzess, Vraylar, Namzaric$224$112,761120 claims
PfizerEliquis$80$101,168133 claims
GSKTrelegy Ellipta$230$86,13386 claims
MerckJanuvia, Janumet$47$70,71183 claims
NovartisEntresto$44$67,30066 claims
BayerKerendia$108$61,46183 claims
Lilly USA, LLCMounjaro$40$35,66534 claims
Johnson & JohnsonXarelto$26$27,86136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →